Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -3982.39% is 183% below its 5-year average of -1409.15%, around the middle of its 5-year range (-12755.62%–-5.89%).
3.00% below its 12-month average of -3866.25%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -5.89%.
EBITDA MARGIN
-3982.39%
EBITDA MARGIN AVG TTM
-3866.25%
EBITDA MARGIN AVG 3Y
-1972.53%
EBITDA MARGIN AVG 5Y
-1409.15%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-3.00%
CURRENT VS 3Y AVG
-101.89%
CURRENT VS 5Y AVG
-182.61%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Aligos Therapeutics, Inc.
Market Cap
$33.42M
EBITDA Margin
-3982.39%
TTM Avg
-3866.25%
3Y Avg
-1972.53%
5Y Avg
-1409.15%
Market Cap
$33.52M
EBITDA Margin
-7905.63%
TTM Avg
-7905.63%
3Y Avg
-7905.63%
5Y Avg
-7905.63%
Market Cap
$32.32M
EBITDA Margin
-2671.72%
TTM Avg
-3785.12%
3Y Avg
-14400.08%
5Y Avg
-14400.08%
Market Cap
$32.31M
EBITDA Margin
-29.82%
TTM Avg
-228.84%
3Y Avg
-176.67%
5Y Avg
-120.12%
Market Cap
$31.36M
EBITDA Margin
-108.41%
TTM Avg
-31.49%
3Y Avg
5.24%
5Y Avg
21.14%
Market Cap
$35.89M
EBITDA Margin
-6.58%
TTM Avg
-1.77%
3Y Avg
-0.14%
5Y Avg
1.64%
Market Cap
$30.65M
EBITDA Margin
-10097.04%
TTM Avg
-6618.17%
3Y Avg
-8743.58%
5Y Avg
-8072.84%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Aligos Therapeutics, Inc. (ALGS) | $33.42M | -3982.39% | -3866.25% | -1972.53% | -1409.15% |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.52M | -7905.63% | -7905.63% | -7905.63% | -7905.63% |
| BeyondSpring Inc. (BYSI)vs › | $32.32M | -2671.72% | -3785.12% | -14400.08% | -14400.08% |
| EUDA Health Holdings Limited (EUDA)vs › | $32.31M | -29.82% | -228.84% | -176.67% | -120.12% |
| Baird Medical Investment Holdings Limited (BDMD)vs › | $31.36M | -108.41% | -31.49% | 5.24% | 21.14% |
| Accuray Incorporated (ARAY)vs › | $35.89M | -6.58% | -1.77% | -0.14% | 1.64% |
| Context Therapeutics Inc. (CNTX)vs › | $30.92M | N/A | N/A | N/A | N/A |
| DocGo Inc. (DCGO)vs › | $36.05M | -22.81% | -7.79% | -0.80% | -0.97% |
| CervoMed Inc. (CRVO)vs › | $30.65M | -10097.04% | -6618.17% | -8743.58% | -8072.84% |
| HeartBeam, Inc. (BEAT)vs › | $36.31M | 31.08% | 27.03% | 24.58% | 21.46% |
Gross Margin
57.5%
EBITDA Margin
-3982.4%
Operating Margin
-4024.9%
Net Margin
-241.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -5.89% |
| 2026-03-31 | -939.33% |
| 2025-12-31 | -12755.62% |
| 2025-09-30 | -3733.20% |
| 2025-06-30 | -1897.20% |
| 2025-03-31 | -6023.47% |
| 2024-12-31 | -3162.48% |
| 2024-09-30 | -1533.81% |
| 2024-06-30 | -2432.05% |
| 2024-03-31 | -2167.55% |
| 2023-12-31 | -940.77% |
| 2023-09-30 | -567.77% |
| 2023-06-30 | -266.80% |
| 2023-03-31 | -847.37% |
| 2022-12-31 | -615.92% |
| 2022-09-30 | -439.41% |
| 2022-06-30 | -528.13% |
| 2022-03-31 | -1344.77% |
| 2021-12-31 | -10064.03% |
| 2021-09-30 | -2088.55% |
| 2021-06-30 | -1853.72% |
| 2021-03-31 | -2952.42% |
